

**In the Claims:**

1. (currently amended) A film-shaped or wafer-shaped pharmaceutical preparation for administering active substances, said preparation containing at least one matrix-forming polymer, said at least one matrix-forming polymer comprising at least one active substance and at least one gas-forming component dissolved or dispersed therein, wherein said at least one gas-forming component comprises at least one carbon dioxide-forming substance which is not combined with an acid, for reducing or completely suppressing an unpleasant taste sensation caused by said at least one active substance.
2. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation is suitable for the administration of said at least one active substance via the oral mucosa.
3. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said at least one carbon dioxide-forming substance is selected from the group consisting of sodium hydrogencarbonate, sodium carbonate, potassium carbonate and potassium hydrogen carbonate.
4. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation contains said at least one carbon dioxide-forming substance in an amount of 2 to 50%-wt relative to the pharmaceutical preparation.
5. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation further comprises at least one additional substance selected from the group consisting of at least one permeation enhancer and at least one blood flow stimulator.

6. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 5, wherein said at least one permeation enhancer is selected from the group consisting of saturated fatty acids, unsaturated fatty acids, hydrocarbons, straight-chain or branched fatty alcohols, dimethyl sulfoxide, propylene glycol, decanol, dodecanol, 2-octyldodecanol, glycerol, isopropylidene glycerol, transcutol (= diethyleneglycol-monoethyl ether), DEET (= N,N-diethyl-m-tolueneamide), solketal, ethanol or other alcohols, menthol and other essential oils or components of essential oils, lauric acid diethanolamide, D-alpha-tocopherol and dexpanthenol.

7. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 5, wherein said at least one blood flow stimulator is selected from the group consisting of menthol, eucalyptol, ginkgo extract, geranium oil, camphor, spearmint oil, oil of juniper, and rosemary.

8. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation disintegrates within 15 minutes after introduction into an aqueous medium.

9. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said at least one matrix-forming polymer is selected from the group consisting of polyvinyl alcohol, cellulose derivatives, starch and starch derivatives, gelatine, polyvinyl pyrrolidone, gum arabic, pullulan, acrylates, polyethylene oxide, copolymers of methyl vinyl ether and maleic acid anhydride.

10. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said at least one matrix-forming polymer is selected from the group consisting of cellulose ether, polyvinyl alcohol, polyurethane,

polymethacrylate, polymethyl methacrylate and derivatives and copolymerisates of each of said polymers.

11. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation further comprises an auxiliary substance for imparting mucoadhesive properties to the preparation.

12. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 11, wherein said auxiliary substance for imparting mucoadhesive properties to said preparation is at least one substance selected from the group consisting of polyacrylic acid, carboxymethyl cellulose, hydroxymethyl cellulose, methyl cellulose, tragacanth, alginic acid, gelatine and gum arabic.

13. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 11, wherein said pharmaceutical preparation includes a bilayer or multilayer structure having at least one layer in contact with said oral mucosa, wherein said at least one layer in contact with the oral mucosa is mucoadhesive, and at least one non-mucoadhesive layer.

14. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 13, wherein said at least one non-mucoadhesive layer has a lower permeability for said at least one active substance.

15. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation is flat-shaped having a density between 0.3 g/cm<sup>3</sup> and 1.7 g/cm<sup>3</sup>.

16. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein the total thickness of said preparation is 5 µm to 10 mm.

17. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation has a shape selected from the group consisting of round, ellipsoid, oval, triangular, quadrangular polygonal, and irregular rounded.

18. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation is present as a solidified foam having a density between 0.01 g/cm<sup>3</sup> and 0.8 g/cm<sup>3</sup>.

19. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein the polymer portion of the matrix has a weight at least between 3%-wt. and 98%-wt relative to the entire preparation.

20. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation further comprises at least one additional auxiliary substance selected from the group consisting of fillers, colourants, disintegrants, emulsifiers, plasticizers, sweeteners, preserving agents, stabilisers, antioxidants and flavouring agents.

21. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation further comprises at least one flavouring agent, at least one sweetener, or at least one plasticizer.

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (previously presented) The film-shaped or wafer-shaped preparation according to claim 4 wherein said preparation contains said at least one carbon dioxide-forming substance in an amount of 5 to 30%-wt relative to the pharmaceutical preparation.
28. (previously presented) The film-shaped or wafer-shaped preparation according to claim 4 wherein said preparation contains said at least one carbon dioxide-forming substance in an amount of 7 to 20%-wt relative to the pharmaceutical preparation.
29. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 8, wherein said preparation disintegrates within 3 minutes after introduction into an aqueous medium.
30. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 8, wherein said preparation disintegrates within 60 seconds after introduction into an aqueous medium.
31. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 9, wherein said cellulose derivatives are selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose and hydroxypropylethyl cellulose.
32. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 10, wherein said cellulose ether is ethyl cellulose.
33. (currently amended) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 15, wherein said preparation has a ~~thickness~~ density between 0.5 g/cm<sup>3</sup> and 1.5 g/cm<sup>3</sup>.

34. (currently amended) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 15, wherein said preparation has a ~~thickness~~ density between 0.7 g/cm<sup>3</sup> and 1.3 g/cm<sup>3</sup>.
35. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 16, wherein the total thickness of said preparation is 30 μm to 2 mm.
36. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 16, wherein the total thickness of said preparation is 0.1 mm to 1 mm.
37. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 18, wherein said solidified foam has a density between 0.08 g/cm<sup>3</sup> and 0.4 g/cm<sup>3</sup>.
38. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 18, wherein said solidified foam has a density between 0.1 g/cm<sup>3</sup> and 0.3 g/cm<sup>3</sup>.
39. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 19, wherein the polymer portion of the matrix has a weight at least between 7 to 80%-wt. relative to the entire preparation.
40. (previously presented) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 19, wherein the polymer portion of the matrix has a weight at least between 20 to 50%-wt. relative to the entire preparation.
41. (currently amended) A method for administering a pharmaceutical preparation containing an active substance having an unpleasant taste and for reducing or suppressing the unpleasant taste of said orally administered pharmaceutically active substance, said method comprising the steps of:

~~preparing a film-shaped or wafer-shaped mucoadhesive pharmaceutical preparation that is disintegratable in an aqueous media of a surface of an oral mucosa of a human or animal organism, comprising the steps of:~~

~~applying at least one matrix-forming polymer to said preparation, said at least one matrix-forming polymer comprising at least one active substance;~~

~~dissolving at least one gas-forming component within said at least one matrix-forming polymer, wherein said at least one gas-forming component comprises at least one carbon dioxide-forming substance for reducing or suppressing said bitter taste;~~

~~adding at least one additional substance to said preparation selected from the group consisting of at least one permeation enhancer and at least one blood flow stimulator;~~

~~adding at least one auxiliary substance to said preparation for imparting mucoadhesive properties to said preparation;~~

~~adding at least one additional auxiliary substance to said preparation selected from the group consisting of fillers, colourants, disintegrants, emulsifiers, plasticizers, sweeteners, preserving agents, stabilisers, antioxidants and flavouring agents; and~~

~~adding at least one flavouring agent, at least one sweetener or at least one plasticizer to said preparation; and~~

providing a film-shaped or wafer-shaped pharmaceutical preparation in accordance with claim 1; and

applying said preparation to ~~[[said]]~~ a surface of ~~[[said]]~~ an oral mucosa of a  
human or animal organism ~~for disintegration in said aqueous media.~~

42. (new) The method according to claim 41, further comprising the step of allowing said preparation to disintegrate upon application to said oral mucosa.

43. (new) The method according to claim 42, wherein said pharmaceutical preparation is not capable of disintegrating in an aqueous medium, further comprising the step of removing the preparation from said oral mucosa after the active substance has been released.